Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Key Resources and Organizations for Precision Medicine Guidelines

MedGenome Strengthens Leadership Team to Drive North American Expansion in Precision Medicine

NCCN Expands Clinical Practice Guidelines for High-Risk Genetic Cancer Assessment

Home
/
update
/
details

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NextEdge Admin

09 Nov 2024

2 min 56 sec

Human Cell Atlas,partnership,genomics,single cell

MGI Tech Co., Ltd. (MGI), a company focused on driving innovation in life science through core tools and technology, has announced a partnership with the Human Cell Atlas (HCA) consortium to advance human cell mapping globally. As part of this collaboration, MGI will provide HCA members with discounted access to its single-cell sequencing and spatial transcriptomics technologies, facilitating broader adoption within the consortium.

“Cutting-edge single cell and spatial genomics are key drivers for the HCA project,” said John Randell, HCA’s Chief Alliance Officer. “MGI’s involvement in our discount program will empower members and accelerate HCA’s progress.”

Through this partnership, HCA researchers gain access to MGI’s scalable, cost-effective solutions in single-cell and spatial omics. MGI will also offer support in experimental design, assay execution, and bioinformatics, aiding members in leveraging its technologies for research.

MGI’s single-cell product line, introduced in 2019, is based on its DNBSEQ™ technology and includes the DNBelab C-TaiM 4, a portable device for high-throughput single-cell 3'RNA, 5'RNA & V(D)J, ATAC analysis. This compact device integrates dual-bead cell capture, microfluidic droplet generation, and advanced computing to enable precise genomic analysis in any setting.

In June 2024, MGI became an official distributor of STOmics products, including Stereo-seq technology, which enhances spatial multi-omics research with nanoscale resolution and unbiased transcriptome capture. Stereo-seq applications span developmental biology, neuroscience, and digital pathology, with 60+ publications in high-impact journals.

Duncan Yu, MGI’s President, expressed pride in supporting HCA’s mission to map human cells and drive discoveries in genomics and disease. Founded in 2016, HCA has grown to over 3,600 members across 100+ countries and produced 400+ publications, offering critical insights into human biology.

MGI will further support HCA at the HCA Asia 2024 Meeting in Hong Kong, December 3-4, fostering idea exchanges and partnership opportunities.